Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conversion Therapy with Irinotecan Liposome-Based Chemoimmunotherapy in Borderline Resectable or Locally Advanced Pancreatic Cancer
ChiCTR2600130597Phase 2Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Aug 2026
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome in pancreatic adenocarcinoma (PDAC), sponsored by Chinese PLA General Hospital. Primary endpoint: R0 resection rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
irinotecan liposome
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2600130597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130597.